<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928368</url>
  </required_header>
  <id_info>
    <org_study_id>20110235</org_study_id>
    <nct_id>NCT01928368</nct_id>
  </id_info>
  <brief_title>A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy&#xD;
      subjects and subjects with mild atopic asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single SC or IV dose administration of AMG 282 to healthy subjects and subjects with mild&#xD;
      atopic asthma will exhibit an acceptable safety and tolerability profile within the dose&#xD;
      ranges studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>Up to day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant vital signs</measure>
    <time_frame>Up to day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results</measure>
    <time_frame>Up to day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant ECG results</measure>
    <time_frame>Up to day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anti-AMG 282 antibodies</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of various PK parameters including tmax, AUClast and Cmax</measure>
    <time_frame>Up to day 141</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Measurement of various pharmacodynamic biomarkers in subjects with mild atopic asthma</measure>
    <time_frame>Up to day 141</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 282</intervention_name>
    <description>Single dose either subcutaneously or intravenously on day 1.</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 282 Matching Placebo</intervention_name>
    <description>Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (All subjects)&#xD;
&#xD;
          -  Is a current non-smoker, has not used any nicotine or tobacco containing products&#xD;
             (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or&#xD;
             nicotine patches) within the last 6 months, and cumulative smoking history is ≤10 pack&#xD;
             years.&#xD;
&#xD;
          -  Females must be of documented non-reproductive potential (ie, postmenopausal [see&#xD;
             definition below]; OR history of hysterectomy; OR history of bilateral salpingectomy;&#xD;
             OR history of bilateral oophorectomy).&#xD;
&#xD;
          -  Body mass index (BMI) between ≥ 18.0 and ≤ 32.0 kg/m2 at screening. (Subjects with&#xD;
             mild atopic asthma only)&#xD;
&#xD;
          -  Documented history of mild, stable atopic asthma within 2 years of screening.&#xD;
&#xD;
          -  Has used only inhaled short-acting β2-agonists (less than twice weekly) to treat&#xD;
             asthma.&#xD;
&#xD;
          -  Pre-bronchodilator forced expiratory volume in 1 second (FEV1) &gt; 70% predicted at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        (All subjects)&#xD;
&#xD;
          -  History or evidence of a clinically significant disorder, condition or disease that,&#xD;
             in the opinion of the Principal Investigator or Amgen medical monitor would pose a&#xD;
             risk to subject safety or interfere with the study evaluation, procedures, or&#xD;
             completion.&#xD;
&#xD;
          -  Subject has a history of residential exposure to tuberculosis without a documented&#xD;
             history of prophylactic treatment of tuberculosis or subject has a positive purified&#xD;
             protein derivative (PPD) or QuantiFERON test at screening. Subjects with a documented&#xD;
             negative PPD or QuantiFERON test within 4 weeks prior to screening who have no known&#xD;
             tuberculosis exposure and have not traveled to an area with tuberculosis do not need&#xD;
             to have a test performed at screening.&#xD;
&#xD;
          -  Has donated or lost ≥ 500 mL of blood or plasma within 8 weeks of administration of&#xD;
             the first dose of IP.&#xD;
&#xD;
        Other criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild asthma</keyword>
  <keyword>Atopic asthma</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>First-in-human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

